title: Tamiflu: what dermatologists need to know.
abstract: This article is a review of this winter's common infections and their treatments. As infectious agents become more aggressive and more resistant, new medications are needed to fight them. The recent outbreak of the H1N1 ("swine flu") influenza strain has increased, by several-fold, the use of the oral antiviral Tamiflu (oseltamivir) and Relenza (zenavimir). -As resistant skin and soft-tissue infections increase in frequency, the use of newer antibiotics is becoming more common. This article reviews the use and cutaneous side effects of antivirals and new antibiotics with a focus on those relevant to the dermatologist.
authors.affiliation: Manhattan Dermatology Associates, USA.
authors.forename: Kendra Gail
authors.initials: KG
authors.lastname: Bergstrom
mesh_terms: D000998:Antiviral Agents / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001711:Biotransformation; D004196:Disease Outbreaks; D003875:Drug Eruptions / Q000453:epidemiology; D006801:Humans; D053118:Influenza A Virus, H1N1 Subtype; D007251:Influenza, Human / Q000188:drug therapy*; D053139:Oseltamivir / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use*
chemical_list: D000998:Antiviral Agents; D053139:Oseltamivir